Zoetis Inc. which can be found using ticker (ZTS) have now 11 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 260 and 195 with the average target price sitting at $222.82. Now with the previous closing price of $167.12 and the analysts are correct then we can expect a percentage increase in value of 33.3%. The day 50 moving average is $178.99 and the 200 day MA is $173.36. The company has a market cap of 75.34B. The current share price for the company is: 163.67 USD
The potential market cap would be $100,450,433,377 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 34.46, revenue per share of 17.69 and a 13.55% return on assets.
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. It commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The Company market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company’s products are sold in more than 100 countries.
